In this study, peptidoglycan microspheres were evaluated for their toxicity and adjuvant effects after oral administration to mice. The liver and spleen indexes, CD cell content in peripheral blood and spleen, and immunoglobulin content in peripheral blood were measured by flow cytometry and indirect ELISA, respectively. Peptidoglycan microspheres with a loading capacity of 46.41 +/- 0.83 g/100 g were prepared. In vivo tests showed that peptidoglycan microspheres revealed an immuno-enhancing profile as indicated by the slow increase of IgG content in peripheral blood compared with that of the untreated peptidoglycan group. In conclusion, peptidoglycan microspheres may be used as a new oral adjuvant in the host.